Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
- @IpsenGroup That’s a wrap on #ESMO17. Ipsen is proud to be part of the knowledge sharing in oncology research .
- @IpsenGroup RT @EFPIA: #WeWontRest until there is a future without #cancer @IpsenGroup #ESMO17 https://t.co/Mq4MkYsLdu https://t.co/wNDzdM4KEL
- @IpsenGroup RT @EFPIA: #WeWontRest until renal cancer becomes a chronic disease @IpsenGroup https://t.co/Mq4MkYsLdu #ESMO17 https://t.co/TsJUdafclM
- @IpsenGroup Thank you all for contributing to an incredible #ESMO17. We are heading home to continue our relentless investigat… https://t.co/Evrc7pRVt8
RESEARCH & DEVELOPMENT
Our commitment is based on a strengthened partnership policy, a promising pipeline, two specialized technological platforms and three benchmark R&D centers across the globe.